Compare Globus Medical Inc. Class A Common Stock (GMED) vs BlackRock TCP Capital Corp (TCPC) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

TCPC trades at $3.98, showing no daily change. The stock exhibits a bullish technical signal, with moving averages supporting an uptrend. Recent Q2 2026 earnings beat expectations at $0.22 per share, and a $523 million portfolio sale has reduced leverage. However, fundamentals show negative revenue and net income trends, with a net loss of $88.93 million in 2025. The company maintains a dividend, with a $0.17 payment scheduled for September 2026.

The outlook is mixed. Positive technicals and strategic portfolio sales provide support, but persistent losses and a class action lawsuit pose significant risks. Analyst sentiment is cautious, with a majority recommending Hold. Investment potential hinges on the success of the strategic review and future profitability improvements amid ongoing financial challenges.